{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:31:09Z","timestamp":1790908269403,"version":"4.1.0"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["GRS 2322\/A\/21"],"award-info":[{"award-number":["GRS 2322\/A\/21"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["SA113P23"],"award-info":[{"award-number":["SA113P23"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","award":["EHD22PI01"],"award-info":[{"award-number":["EHD22PI01"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","award":["CB06\/04\/0023"],"award-info":[{"award-number":["CB06\/04\/0023"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["EDU\/48\/2026"],"award-info":[{"award-number":["EDU\/48\/2026"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["EDU\/1868\/2022"],"award-info":[{"award-number":["EDU\/1868\/2022"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/00681"],"award-info":[{"award-number":["PI23\/00681"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/00526"],"award-info":[{"award-number":["PI22\/00526"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI25\/00628\\u2033"],"award-info":[{"award-number":["PI25\/00628\\u2033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118111","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:20:37Z","timestamp":1780154437000},"page":"118111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Impact of CD44 alternative splicing on the response to anticancer drugs"],"prefix":"10.1016","volume":"251","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-6849","authenticated-orcid":false,"given":"Jose J.G.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitane","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"\u00c1lvarez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazaret","family":"Hortelano-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Delgado-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca P.","family":"Marijuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Perez-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura O.","family":"Benizri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Gallai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Reviejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/cancers17030441","article-title":"heterogeneity in cancer","volume":"17","author":"MacDonald","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0015","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/156652409789839125","article-title":"Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours","volume":"9","author":"Marin","year":"2009","journal-title":"Curr. Mol. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12032-023-02138-y","article-title":"Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role","volume":"40","author":"Kannampuzha","year":"2023","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118111_b0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/092986710790514462","article-title":"Molecular bases of liver cancer refractoriness to pharmacological treatment","volume":"17","author":"Marin","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0041-1735631","article-title":"Mechanisms of pharmacoresistance in hepatocellular carcinoma: new drugs but old problems","volume":"42","author":"Marin","year":"2022","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.bcp.2026.118111_b0035","article-title":"Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells","volume":"165","author":"Sanchez-Martin","year":"2023","journal-title":"Biomed. Pharmacother. Biomedecine & Pharmacotherapie"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0040","article-title":"The cancer stem cell phenotype: you can't win until you learn how to lose it","volume":"2","author":"Lopez-Bertoni","year":"2015","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.bcp.2026.118111_b0045","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118111_b0055","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fonc.2019.00626","article-title":"Stem cell plasticity and dormancy in the development of cancer therapy resistance","volume":"9","author":"De Angelis","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0060","first-page":"684","article-title":"Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer","volume":"4","author":"Zhang","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bcp.2026.118111_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2087204","article-title":"The importance of CD44 as a stem cell biomarker and therapeutic target in cancer","volume":"2016","author":"Thapa","year":"2016","journal-title":"Stem Cells Int."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0070","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","article-title":"Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target","volume":"4","author":"Yan","year":"2015","journal-title":"Stem Cells Transl. Med."},{"issue":"24","key":"10.1016\/j.bcp.2026.118111_b0075","doi-asserted-by":"crossref","first-page":"12160","DOI":"10.1073\/pnas.89.24.12160","article-title":"Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons","volume":"89","author":"Screaton","year":"1992","journal-title":"PNAS"},{"issue":"17","key":"10.1016\/j.bcp.2026.118111_b0080","doi-asserted-by":"crossref","first-page":"12235","DOI":"10.1016\/S0021-9258(18)31376-0","article-title":"The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat","volume":"268","author":"Screaton","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0085","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/biom11121850","article-title":"CD44: a multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0090","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/biom13071047","article-title":"Prediction of CD44 structure by deep learning-based protein modeling","volume":"13","author":"Camponeschi","year":"2023","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0095","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0092-8674(90)90694-A","article-title":"CD44 is the principal cell surface receptor for hyaluronate","volume":"61","author":"Aruffo","year":"1990","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0100","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1096\/fj.202000380RR","article-title":"The role of CD44 in pathological angiogenesis","volume":"34","author":"Chen","year":"2020","journal-title":"FASEB J."},{"issue":"20","key":"10.1016\/j.bcp.2026.118111_b0105","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.3390\/cancers15205041","article-title":"CD44 intracellular domain: a long tale of a short tail","volume":"15","author":"Skandalis","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0110","doi-asserted-by":"crossref","first-page":"10531","DOI":"10.1074\/jbc.M108654200","article-title":"A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells","volume":"277","author":"Jiang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/ijms21010336","article-title":"Structural characterization of the CD44 stem region for standard and cancer-associated isoforms","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2023.151360","article-title":"N-glycosylation at N57\/100\/110 affects CD44s localization, function and stability in hepatocellular carcinoma","volume":"102","author":"Cheng","year":"2023","journal-title":"Eur. J. Cell Biol."},{"issue":"5390","key":"10.1016\/j.bcp.2026.118111_b0125","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1126\/science.282.5390.941","article-title":"TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation","volume":"282","author":"Maiti","year":"1998","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/jomfp.JOMFP_246_18","article-title":"Structure, function and role of CD44 in neoplasia","volume":"23","author":"Mishra","year":"2019","journal-title":"J. Oral Maxillof. Pathol.: JOMFP"},{"key":"10.1016\/j.bcp.2026.118111_b0135","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.2147\/CMAR.S175681","article-title":"CD44 is overexpressed and correlated with tumor progression in gallbladder cancer","volume":"10","author":"He","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0140","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4","article-title":"Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro","volume":"66","author":"Trochon","year":"1996","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0145","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4049\/jimmunol.143.3.798","article-title":"CD44 contributes to T cell activation","volume":"143","author":"Huet","year":"1989","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tem.2022.02.002","article-title":"The membrane receptor CD44: novel insights into metabolism","volume":"33","author":"Weng","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0155","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1083\/jcb.140.4.885","article-title":"Ezrin\/radixin\/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2","volume":"140","author":"Yonemura","year":"1998","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0160","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1083\/jcb.108.4.1557","article-title":"The hyaluronate receptor is preferentially expressed on proliferating epithelial cells","volume":"108","author":"Alho","year":"1989","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/abbs\/gmu042","article-title":"CD44 clustering is involved in monocyte differentiation","volume":"46","author":"Zhang","year":"2014","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0170","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1172\/JCI4235","article-title":"Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity","volume":"102","author":"Estess","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0175","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0014-4827(88)90393-X","article-title":"Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor","volume":"178","author":"Green","year":"1988","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0180","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1172\/JCI2494","article-title":"Two different functions for CD44 proteins in human myelopoiesis","volume":"102","author":"Moll","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1172\/JCI12980","article-title":"Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival","volume":"107","author":"Denhardt","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118111_b0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cca.2007.06.001","article-title":"Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer","volume":"384","author":"Huang","year":"2007","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1349-7006.2000.tb00960.x","article-title":"Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma","volume":"91","author":"Kanke","year":"2000","journal-title":"Japan. J. Cancer Res.: Gann"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/gut.46.1.14","article-title":"Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma","volume":"46","author":"Gotoda","year":"2000","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0205","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.5301\/jbm.5000091","article-title":"Expression profile of standard and variants forms of CD44 related to prostate cancer behavior","volume":"30","author":"Moura","year":"2015","journal-title":"Int. J. Biol. Markers"},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0210","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2014.253","article-title":"Prognostic significance of CD44 variant 2 upregulation in colorectal cancer","volume":"111","author":"Ozawa","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118111_b0215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fonc.2019.00309","article-title":"The prognostic and clinical value of CD44 in colorectal cancer: a meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0220","first-page":"887","article-title":"Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3","volume":"63","author":"Barbour","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118111_b0225","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1471-2407-11-418","article-title":"CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers","volume":"11","author":"Olsson","year":"2011","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.bcp.2026.118111_b0230","doi-asserted-by":"crossref","first-page":"12061","DOI":"10.3390\/ijms232012061","article-title":"CD44V3, an alternatively spliced form of CD44, promotes pancreatic cancer progression","volume":"23","author":"Zhu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3892\/ol.2024.14213","article-title":"Prognostic effect of programmed cell death ligand 1\/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma","volume":"27","author":"Todoroki","year":"2024","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21873\/cgp.20260","article-title":"Altered expression of MBNL family of alternative splicing factors in colorectal cancer","volume":"18","author":"Navvabi","year":"2021","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.bcp.2026.118111_b0245","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1476-4598-9-72","article-title":"PCBP-1 regulates alternative splicing of the CD44 gene and inhibits invasion in human hepatoma cell line HepG2 cells","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0250","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10120-022-01357-y","article-title":"CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma","volume":"26","author":"Giraud","year":"2023","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0255","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1747732","article-title":"CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity","volume":"9","author":"Theodoraki","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0260","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-022-02314-4","article-title":"Direct interaction of TrkA\/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells","volume":"41","author":"Trouvilliez","year":"2022","journal-title":"J. Experiment. Clin. Cancer Res.: CR"},{"issue":"8","key":"10.1016\/j.bcp.2026.118111_b0265","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1111\/cas.15353","article-title":"CD44v3,8-10 is essential for slug-dependent vimentin gene expression to acquire TGF-beta1-induced tumor cell motility","volume":"113","author":"Qiu","year":"2022","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0270","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-04-3294","article-title":"Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene","volume":"66","author":"Watermann","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0275","doi-asserted-by":"crossref","first-page":"e1826","DOI":"10.1371\/journal.pone.0001826","article-title":"CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration","volume":"3","author":"Zen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118111_b0280","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.oraloncology.2018.09.028","article-title":"Crosstalk between Raf-MEK-ERK and PI3K-akt-GSK3beta signaling networks promotes chemoresistance, invasion\/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer","volume":"86","author":"Kashyap","year":"2018","journal-title":"Oral Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0285","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/biology10101007","article-title":"Deciphering the molecular machinery-influence of sE-cadherin on tumorigenic traits of prostate cancer cells","volume":"10","author":"Tsaur","year":"2021","journal-title":"Biology"},{"issue":"47","key":"10.1016\/j.bcp.2026.118111_b0290","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.3748\/wjg.v11.i47.7401","article-title":"Expression of human chorionic gonadotropin, CD44v6 and CD44v4\/5 in esophageal squamous cell carcinoma","volume":"11","author":"Li","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0295","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1593\/neo.122010","article-title":"Exosomal tumor microRNA modulates premetastatic organ cells","volume":"15","author":"Rana","year":"2013","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0300","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41419-023-05924-8","article-title":"Long noncoding RNA LINC01594 inhibits the CELF6-mediated splicing of oncogenic CD44 variants to promote colorectal cancer metastasis","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0305","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/onc.2012.611","article-title":"Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling","volume":"33","author":"Zeilstra","year":"2014","journal-title":"Oncogene"},{"issue":"6916","key":"10.1016\/j.bcp.2026.118111_b0310","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nature01153","article-title":"Signal-dependent regulation of splicing via phosphorylation of Sam68","volume":"420","author":"Matter","year":"2002","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0315","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/MCB.26.1.362-370.2006","article-title":"Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion","volume":"26","author":"Cheng","year":"2006","journal-title":"Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0320","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C","article-title":"Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer","volume":"183","author":"Muller","year":"1997","journal-title":"J. Pathol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0325","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00432-004-0596-1","article-title":"Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer","volume":"130","author":"Vizoso","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0168-8278(00)80192-0","article-title":"Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival","volume":"32","author":"Endo","year":"2000","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0335","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/bjc.1997.611","article-title":"High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer","volume":"76","author":"Zeimet","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0340","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/pcmr.12307","article-title":"Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome","volume":"28","author":"Marzese","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0345","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ijc.27742","article-title":"Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma","volume":"132","author":"Zhou","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0350","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3892\/or.2015.4110","article-title":"CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer","volume":"34","author":"Loh","year":"2015","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0355","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/gutjnl-2016-312927","article-title":"HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of CD44 during epithelial-mesenchymal transition","volume":"67","author":"Sakuma","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0360","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stem.2014.01.009","article-title":"CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis","volume":"14","author":"Todaro","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0365","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00535-026-02343-2","article-title":"Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma","volume":"61","author":"Uematsu","year":"2026","journal-title":"J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0370","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/0959-8049(95)00353-K","article-title":"Prognostic value of CD44 splice variants in human stage III cervical cancer","volume":"31A","author":"Kainz","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118111_b0375","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2022.07.073","article-title":"The RNA-binding proteins CELF1 and ELAVL1 cooperatively control the alternative splicing of CD44","volume":"626","author":"David","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0380","first-page":"88","article-title":"Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression","volume":"2","author":"Yang","year":"2010","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0385","first-page":"80","article-title":"Silibinin suppresses CD44 expression in prostate cancer cells","volume":"1","author":"Handorean","year":"2009","journal-title":"Am. J. Transl. Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0390","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1101\/gad.241968.114","article-title":"Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing","volume":"28","author":"Xu","year":"2014","journal-title":"Genes Dev."},{"issue":"13","key":"10.1016\/j.bcp.2026.118111_b0395","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/0008-5472.CAN-12-1343","article-title":"Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing","volume":"73","author":"Zeng","year":"2013","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0400","doi-asserted-by":"crossref","first-page":"612","DOI":"10.5483\/BMBRep.2016.49.11.118","article-title":"SR proteins regulate V6 exon splicing of CD44 pre-mRNA","volume":"49","author":"Loh","year":"2016","journal-title":"BMB Rep."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0405","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/0008-5472.CAN-13-2309","article-title":"CD44v8-10 is a cancer-specific marker for gastric cancer stem cells","volume":"74","author":"Lau","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0410","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2195363","article-title":"The v8-10 variant isoform of CD44 is selectively expressed in the normal human colonic stem cell niche and frequently is overexpressed in colon carcinomas during tumor development","volume":"24","author":"Boman","year":"2023","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0415","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.1996.14.4.1122","article-title":"Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients","volume":"14","author":"Yamaguchi","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0420","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0022-5347(05)65282-2","article-title":"Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer","volume":"167","author":"Miyake","year":"2002","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0425","first-page":"541","article-title":"Expression of variant CD44 containing variant exon v8-10 in gallbladder cancer","volume":"7","author":"Yamaguchi","year":"2000","journal-title":"Oncol. Rep."},{"issue":"79","key":"10.1016\/j.bcp.2026.118111_b0430","doi-asserted-by":"crossref","first-page":"34876","DOI":"10.18632\/oncotarget.26172","article-title":"High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy","volume":"9","author":"Kagami","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156595","article-title":"CD44 splice variant v8-10 as a marker of serous ovarian cancer prognosis","volume":"11","author":"Sosulski","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0440","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jcmgh.2019.05.008","article-title":"Cancer stem-cell marker CD44v9-positive cells arise from Helicobacter pylori-infected CAPZA1-overexpressing cells","volume":"8","author":"Tsugawa","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0445","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1002\/cam4.1874","article-title":"CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma","volume":"7","author":"Taniguchi","year":"2018","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118111_b0450","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/cancers16081556","article-title":"Presence of CD44v9-expressing cancer stem cells in circulating tumor cells and effects of carcinoembryonic antigen levels on the prognosis of colorectal cancer","volume":"16","author":"Sawai","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.118111_b0455","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fcell.2020.00417","article-title":"CD44v9 induces stem cell-like phenotypes in human cholangiocarcinoma","volume":"8","author":"Suwannakul","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3835(98)00088-3","article-title":"Relationship between CD44 expression and differentiation of human prostate adenocarcinomas","volume":"129","author":"Takahashi","year":"1998","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0465","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000078670","article-title":"Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells","volume":"71","author":"Sato","year":"2004","journal-title":"Pathobiology"},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0470","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.3390\/cancers12113195","article-title":"Opposite roles of Tra2beta and SRSF9 in the v10 exon splicing of CD44","volume":"12","author":"Oh","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102588","article-title":"Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis","volume":"298","author":"Guo","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0480","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00008390-199906000-00003","article-title":"CD44 variant isoform CD44v10 expression of human melanoma cell lines is upregulated by hyaluronate and correlates with migration","volume":"9","author":"Yoshinari","year":"1999","journal-title":"Melanoma Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0485","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1046\/j.1464-410x.2000.00483.x","article-title":"Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma","volume":"85","author":"Li","year":"2000","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0490","doi-asserted-by":"crossref","DOI":"10.1093\/glycob\/cwaf020","article-title":"Ephrin-B1 regulates cell surface residency of heparan sulfate proteoglycans (HSPGs) and complexes with the HSPG CD44V3-10 and fibroblast growth factor receptors","volume":"35","author":"Prydz","year":"2025","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0495","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mc.23479","article-title":"Sulforaphane inhibits CD44v6\/YAP1\/TEAD signaling to suppress the cancer phenotype","volume":"62","author":"Chen","year":"2023","journal-title":"Mol. Carcinog."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0500","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3892\/or.2013.2273","article-title":"CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer","volume":"29","author":"Saito","year":"2013","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0505","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.molcel.2009.01.025","article-title":"ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing","volume":"33","author":"Warzecha","year":"2009","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0510","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.3390\/ijms25063141","article-title":"Role of CD44 in chemotherapy treatment outcome: a scoping review of clinical studies","volume":"25","author":"Wu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0515","first-page":"5955","article-title":"CD44 expression enhances chemoresistance and implies occult micrometastases after conversion hepatectomy for initially unresectable colorectal liver metastases","volume":"12","author":"Hayashi","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0520","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118111_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174147","article-title":"The role of CD44 in cancer chemoresistance: a concise review","volume":"903","author":"Yaghobi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118111_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1508577","article-title":"CD44 variant exons induce chemoresistance by modulating cell death pathways","volume":"13","author":"Yanova","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0535","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ajpath.2010.11.077","article-title":"Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance","volume":"178","author":"Wang","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0540","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1002\/mco2.554","article-title":"CD44 and its implication in neoplastic diseases","volume":"5","author":"Xu","year":"2024","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0545","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcmgh.2017.03.003","article-title":"Initiation and maintenance of gastric cancer: a focus on CD44 variant isoforms and cancer stem cells","volume":"4","author":"Zavros","year":"2017","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2026.118111_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122345","article-title":"CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3\/STAT3 signaling pathway","volume":"336","author":"Liu","year":"2024","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0555","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.7150\/jca.19732","article-title":"Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma","volume":"8","author":"Nishino","year":"2017","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0560","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s13046-019-1508-1","article-title":"Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway","volume":"38","author":"Wang","year":"2019","journal-title":"J. Experiment. Clin. Cancer Res.: CR"},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0565","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.21873\/anticanres.12969","article-title":"Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression","volume":"38","author":"Miyoshi","year":"2018","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0570","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/pros.22775","article-title":"CD44 variant 6 is associated with prostate cancer metastasis and chemo-\/radioresistance","volume":"74","author":"Ni","year":"2014","journal-title":"Prostate"},{"issue":"13","key":"10.1016\/j.bcp.2026.118111_b0575","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1111\/bph.15030","article-title":"A low MW inhibitor of CD44 dimerization for the treatment of glioblastoma","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111850","article-title":"CD44 variant 6 is associated with prostate cancer growth and chemo-\/radiotherapy response in vivo","volume":"388","author":"Ni","year":"2020","journal-title":"Exp. Cell Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0585","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41416-019-0600-9","article-title":"In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells","volume":"121","author":"Mashima","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"20","key":"10.1016\/j.bcp.2026.118111_b0590","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1158\/0008-5472.CAN-09-0834","article-title":"Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high\/CD24low\/HER2low breast cancer stem cells","volume":"69","author":"Reim","year":"2009","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0595","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1017\/S0022215116008525","article-title":"Expression of CD44 variant isoforms, CD44v3 and CD44v6, are associated with prognosis in nasopharyngeal carcinoma","volume":"130","author":"Sagawa","year":"2016","journal-title":"J. Laryngol. Otol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0600","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1245\/s10434-018-07126-5","article-title":"Effect of c-Met and CD44v6 expression in resistance to chemotherapy in esophageal squamous cell carcinoma","volume":"26","author":"Hara","year":"2019","journal-title":"Ann. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0605","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1007\/s13277-015-4755-6","article-title":"Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells","volume":"37","author":"Lv","year":"2016","journal-title":"Tumour Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118111_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.03.015","article-title":"Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality","volume":"34","author":"Hagiwara","year":"2016","journal-title":"Urol. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118111_b0615","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.humpath.2013.02.016","article-title":"CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis","volume":"44","author":"Zhang","year":"2013","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0620","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","author":"Zoller","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.bcp.2026.118111_b0625","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1158\/1078-0432.CCR-15-3115","article-title":"CD44 expression level and isoform contributes to pancreatic cancer cell plasticity, invasiveness, and response to therapy","volume":"22","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0630","first-page":"42","article-title":"Comprehensive analysis of CD44 in colorectal cancer: molecular mechanisms, isoform interactions, and targeted treatments to address tumorigenesis and chemoresistance","volume":"41","author":"Jha","year":"2026","journal-title":"Cancer Biother. Radiopharm."},{"issue":"44","key":"10.1016\/j.bcp.2026.118111_b0635","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1038\/onc.2012.638","article-title":"Redox regulation in stem-like cancer cells by CD44 variant isoforms","volume":"32","author":"Nagano","year":"2013","journal-title":"Oncogene"},{"issue":"39","key":"10.1016\/j.bcp.2026.118111_b0640","doi-asserted-by":"crossref","first-page":"32800","DOI":"10.1074\/jbc.M111.308528","article-title":"Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma","volume":"287","author":"Bourguignon","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0645","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/17425255.2019.1631285","article-title":"What \u201cthe Cancer Genome Atlas\u201d database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs","volume":"15","author":"Briz","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118111_b0650","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.3390\/ijms23158616","article-title":"CD44 contributes to the regulation of MDR1 protein and doxorubicin chemoresistance in osteosarcoma","volume":"23","author":"Gerardo-Ramirez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"28","key":"10.1016\/j.bcp.2026.118111_b0655","doi-asserted-by":"crossref","first-page":"26308","DOI":"10.18632\/oncotarget.4763","article-title":"CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination","volume":"6","author":"Ravindranath","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118111_b0660","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/1471-2407-13-476","article-title":"Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer","volume":"13","author":"Ricciardelli","year":"2013","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.bcp.2026.118111_b0665","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.7150\/thno.98389","article-title":"BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN\/AKT\/beta-catenin pathway","volume":"14","author":"Cao","year":"2024","journal-title":"Theranostics"},{"issue":"1\u20134","key":"10.1016\/j.bcp.2026.118111_b0670","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bbrc.2018.11.055","article-title":"CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549\u00a0cells","volume":"507","author":"Horibe","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0675","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12885-018-3988-3","article-title":"Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer","volume":"18","author":"Hagiwara","year":"2018","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.118111_b0680","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.7150\/thno.14848","article-title":"Redox Regulation of Stem-like Cells though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications","volume":"6","author":"Ju","year":"2016","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0685","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0690","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","article-title":"Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer","volume":"38","author":"Koppula","year":"2018","journal-title":"Cancer Commun. (Lond)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0695","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/cas.12967","article-title":"CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment","volume":"107","author":"Thanee","year":"2016","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0700","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/0008-5472.CAN-12-3609-T","article-title":"xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma","volume":"73","author":"Yoshikawa","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0705","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10120-021-01194-5","article-title":"Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation","volume":"24","author":"Jogo","year":"2021","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0710","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archoto.2010.25","article-title":"Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of rho kinase and PI-3 kinase signaling","volume":"136","author":"Torre","year":"2010","journal-title":"Arch. Otolaryngol.\u2013Head Neck Surg."},{"issue":"39","key":"10.1016\/j.bcp.2026.118111_b0715","doi-asserted-by":"crossref","first-page":"26533","DOI":"10.1074\/jbc.M109.027466","volume":"284","author":"Bourguignon","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0720","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41419-020-03037-0","article-title":"CD44\/HA signaling mediates acquired resistance to a PI3Kalpha inhibitor","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0725","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/cells8040295","article-title":"CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of hippo-yap signaling","volume":"8","author":"Lai","year":"2019","journal-title":"Cells"},{"issue":"43","key":"10.1016\/j.bcp.2026.118111_b0730","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1038\/onc.2012.542","article-title":"CD44 promotes Kras-dependent lung adenocarcinoma","volume":"32","author":"Zhao","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118111_b0735","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mehy.2018.09.002","article-title":"The CD44 variant induces K562 cell acquired with resistance to adriamycin via NF-kappaB\/Snail\/Bcl-2 pathway","volume":"121","author":"Fan","year":"2018","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bcp.2026.118111_b0740","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fimmu.2015.00154","article-title":"CD44 Acts as a signaling platform controlling tumor progression and metastasis","volume":"6","author":"Orian-Rousseau","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118111_b0745","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/OTT.S226951","article-title":"Foretinib inhibits cancer stemness and gastric cancer cell proliferation by decreasing CD44 and c-MET signaling","volume":"13","author":"Sohn","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0750","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0755","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0760","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbrc.2016.06.077","article-title":"Synergistic effects of CD44 and TGF-beta1 through AKT\/GSK-3beta\/beta-catenin signaling during epithelial-mesenchymal transition in liver cancer cells","volume":"477","author":"Park","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0765","first-page":"211","article-title":"CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion","volume":"41","author":"Cho","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0770","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12943-023-01877-w","article-title":"Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer","volume":"22","author":"Zeng","year":"2023","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.bcp.2026.118111_b0775","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2174\/1871520618666180611112125","article-title":"Verbascoside attenuates Rac-1 and HIF-1alpha signaling cascade in colorectal cancer cells","volume":"18","author":"Seyfi","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bcp.2026.118111_b0780","article-title":"Role of tumor suppressor genes P53 and PTEN in CD44-mediated gastric adenocarcinoma multidrug resistance","volume":"187","author":"Perez-Silva","year":"2025","journal-title":"Biomed. Pharmacother. = Biomedecine & Pharmacotherapie"},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0785","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/molecules24112191","article-title":"In vitro human metabolism and inhibition potency of verbascoside for CYP enzymes","volume":"24","author":"Reid","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118111_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118039","article-title":"CD44-targeted N-benzyltetrahydroisoquinoline derivatives as anticancer agents with high tumor-to-normal cell selectivity","volume":"298","author":"Romero-Tamudo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118111_b0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115570","article-title":"N-aryltetrahydroisoquinoline derivatives as HA-CD44 interaction inhibitors: Design, synthesis, computational studies, and antitumor effect","volume":"258","author":"Espejo-Roman","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0800","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MPA.0000000000000741","article-title":"4-Methylumbelliferone suppresses hyaluronan synthesis and tumor progression in SCID mice intra-abdominally inoculated with pancreatic cancer cells","volume":"46","author":"Nagase","year":"2017","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0805","first-page":"29","article-title":"4-Methylumbelliferone as a potent and selective antitumor drug on a glioblastoma model","volume":"31","author":"Pibuel","year":"2021","journal-title":"Glycobiology"},{"key":"10.1016\/j.bcp.2026.118111_b0810","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jsbmb.2016.12.001","article-title":"Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer","volume":"173","author":"Shan","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054020","article-title":"Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer","volume":"8","author":"So","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0820","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/mol.110.068403","article-title":"A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer","volume":"79","author":"So","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0825","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3892\/or.2014.3514","article-title":"Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells","volume":"32","author":"Kim","year":"2014","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0830","first-page":"39","article-title":"Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling","volume":"35","author":"Chung","year":"2015","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0835","doi-asserted-by":"crossref","first-page":"16985","DOI":"10.1038\/s41598-018-35069-0","article-title":"Silibinin, a natural blend in polytherapy formulation for targeting Cd44v6 expressing colon cancer stem cells","volume":"8","author":"Patel","year":"2018","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0840","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/mc.22901","article-title":"EGCG inhibits CSC-like properties through targeting miR-485\/CD44 axis in A549-cisplatin resistant cells","volume":"57","author":"Jiang","year":"2018","journal-title":"Mol. Carcinog."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0845","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3892\/or.2013.2893","article-title":"Genistein attenuates cancer stem cell characteristics in gastric cancer through the downregulation of Gli1","volume":"31","author":"Yu","year":"2014","journal-title":"Oncol. Rep."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118111_b0850","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11010-017-3171-1","article-title":"Chlorogenic acid regulates apoptosis and stem cell marker-related gene expression in A549 human lung cancer cells","volume":"441","author":"Yamagata","year":"2018","journal-title":"Mol. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0855","first-page":"1999","article-title":"Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck","volume":"41","author":"Colnot","year":"2000","journal-title":"J. Nucl. Med."},{"issue":"10 Pt 2","key":"10.1016\/j.bcp.2026.118111_b0860","first-page":"3961S","article-title":"Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma","volume":"9","author":"Borjesson","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0865","first-page":"3401","article-title":"Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study","volume":"8","author":"Colnot","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"20 Pt 1","key":"10.1016\/j.bcp.2026.118111_b0870","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0875","first-page":"927","article-title":"Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck","volume":"30","author":"Sauter","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118111_b0880","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e32801403f4","article-title":"Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study","volume":"18","author":"Rupp","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"22","key":"10.1016\/j.bcp.2026.118111_b0885","doi-asserted-by":"crossref","first-page":"32532","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0890","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159716","article-title":"Targeting tumor cells with anti-CD44 antibody triggers macrophage-mediated immune modulatory effects in a cancer xenograft model","volume":"11","author":"Maisel","year":"2016","journal-title":"PLoS One"},{"issue":"48","key":"10.1016\/j.bcp.2026.118111_b0895","doi-asserted-by":"crossref","first-page":"80046","DOI":"10.18632\/oncotarget.11098","article-title":"First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors","volume":"7","author":"Menke-van der Houven van Oordt","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0900","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-018-0358-8","article-title":"Menke-van der Houven van Oordt, Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody","volume":"8","author":"Jauw","year":"2018","journal-title":"EJNMMI Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.118111_b0905","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1541-7786.MCR-17-0333","article-title":"Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-based NIR-PIT","volume":"15","author":"Nagaya","year":"2017","journal-title":"Mol. Cancer Res.: MCR"},{"key":"10.1016\/j.bcp.2026.118111_b0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150534","article-title":"Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer model","volume":"737","author":"Yaku","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118111_b0915","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4149\/neo_2014_035","article-title":"Efficient inhibition of intraperitoneal human ovarian cancer growth by short hairpin RNA targeting CD44","volume":"61","author":"Zou","year":"2014","journal-title":"Neoplasma"},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0920","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00280-008-0684-z","article-title":"Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion","volume":"62","author":"Xie","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0925","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/mt.2008.235","article-title":"RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells","volume":"17","author":"Mi","year":"2009","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118111_b0930","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/nat.2013.0423","article-title":"In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker","volume":"23","author":"Ababneh","year":"2013","journal-title":"Nucleic Acid Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118111_b0935","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/bioengineering12020113","article-title":"Development and characterization of CD44-Targeted X-aptamers with enhanced binding affinity for cancer therapeutics","volume":"12","author":"Wang","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.bcp.2026.118111_b0940","first-page":"443","article-title":"A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth","volume":"50","author":"Caliendo","year":"2025","journal-title":"Bioact. Mater."},{"issue":"5","key":"10.1016\/j.bcp.2026.118111_b0945","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.7150\/thno.17826","article-title":"Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth","volume":"7","author":"Zheng","year":"2017","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.bcp.2026.118111_b0950","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4155\/tde-2021-0038","article-title":"Targeted delivery of doxorubicin through CD44 aptamer to cancer cells","volume":"12","author":"Natesh","year":"2021","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.bcp.2026.118111_b0955","first-page":"192","article-title":"Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells","volume":"19","author":"Huang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2026.118111_b0960","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6253978","article-title":"Anti-CD44 and EGFR dual-targeted solid lipid nanoparticles for delivery of doxorubicin to triple-negative breast cancer cell line: preparation, statistical optimization, and in vitro characterization","volume":"2022","author":"Darabi","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bcp.2026.118111_b0965","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fimmu.2015.00135","article-title":"Modulation of CD44 activity by A6-peptide","volume":"6","author":"Finlayson","year":"2015","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0970","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3390\/ijms25074102","article-title":"Informed by cancer stem cells of solid tumors: advances in treatments targeting tumor-promoting factors and pathways","volume":"25","author":"MacLean","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.118111_b0975","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/ijgc-2021-003316","article-title":"Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer","volume":"32","author":"Girda","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.bcp.2026.118111_b0980","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jconrel.2020.10.005","article-title":"A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia","volume":"329","author":"Gu","year":"2021","journal-title":"J. Control. Release"},{"issue":"11\u201312","key":"10.1016\/j.bcp.2026.118111_b0985","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00109-025-02601-5","article-title":"Peptide-based inhibition of CD44v6 renders liver carcinomas more susceptible to therapeutic intervention","volume":"103","author":"Srikanth","year":"2025","journal-title":"J. Mol. Med. (Berl)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118111_b0990","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219697","article-title":"Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFbeta-hyaluronan-CD44 signalling pathway","volume":"14","author":"Sarkar","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bcp.2026.118111_b0995","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41419-020-03180-8","article-title":"Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro","volume":"11","author":"Dituri","year":"2020","journal-title":"Cell Death Dis."},{"issue":"22","key":"10.1016\/j.bcp.2026.118111_b1000","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/cancers17223657","article-title":"CD44v9 expression in pretreatment biopsies as a predictor of chemotherapy resistance in gastric cancer","volume":"17","author":"Sawai","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.118111_b1005","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1586367","article-title":"CD44 variant exon 6 isoform expression as a potential predictor of lymph node metastasis in invasive breast carcinoma of no special type","volume":"2021","author":"Rustamadji","year":"2021","journal-title":"Int. J. Breast Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:31:11Z","timestamp":1783920671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":201,"alternative-id":["S0006295226004466"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118111","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of CD44 alternative splicing on the response to anticancer drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118111"}}